Net Income per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net Income per Share [Abstract]
Net income		$ 7,027	$ 5,545	$ 12,146	$ 16,766
Basic [Abstract]
Weighted-average shares of common stock outstanding		32,673	34,128	32,997	34,040
Shares used in computing basic net income per share (in shares)		32,673	34,128	32,997	34,040
Effect of dilutive securities:
Restricted stock subject to vesting (in shares)		459	479	450	468
Contingently issuable shares (in shares)		0	0	0	2	[1]
Shares issuable for acquisition consideration (in shares)	[2]	859	470	638	502
Shares used in computing diluted net income per share (in shares)		33,991	35,077	34,085	35,012
Basic net income per share (in dollars per share)		$ 0.22	$ 0.16	$ 0.37	$ 0.49
Diluted net income per share (in dollars per share)		$ 0.21	$ 0.16	$ 0.36	$ 0.48
Anti-dilutive options and restricted stock not included in the calculation of diluted net income per share (in shares)		0	0	117	0

[1] For the nine months ended September 30, 2016, this represents the shares issued to Zeon Solutions Incorporated and certain related entities (collectively, "Zeon") pursuant to the Asset Purchase Agreement.

[2] For the three and nine months ended September 30, 2017, this represents the shares held in escrow pursuant to: (i) the Asset Purchase Agreement with BioPharm Systems, Inc. ("BioPharm"); (ii) the Asset Purchase Agreement with Zeon; (iii) the Asset Purchase Agreement with The Pup Group, Inc. d/b/a Enlighten ("Enlighten"); (iv) the Asset Purchase Agreement with RAS & Associates, LLC ("RAS"); and (v) the Asset Purchase Agreement with Clarity Consulting, Inc. and Truth Labs, LLC. (together, "Clarity"), as part of the consideration. For the three and nine months ended September 30, 2016, this represents the shares held in escrow pursuant to: (i) the Asset Purchase Agreement with BioPharm; (ii) the Asset Purchase Agreement with Zeon; (iii) the Stock Purchase Agreement for Market Street Solutions, Inc. ("Market Street"); and (iv) the Asset Purchase Agreement with Enlighten, as part of the consideration.